Taribavirin for the treatment of chronic hepatitis C

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 18, 2008, Pages 3243-3249

  Kearney, Keith R ^a   Thornton, James J ^a   Navarro, Victor J ^b  

^a LANKENAU HOSPITAL   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

hepatitis C; PEG IFN; ribavirin; SVR; taribavirin

Indexed keywords

DRUG DERIVATIVE; PRODRUG; RIBAVIRIN; TARIBAVIRIN;

ANEMIA; ANIMAL; CHEMICALLY INDUCED DISORDER; HEPATITIS C; HUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; TREATMENT OUTCOME; VIROLOGY;

ANEMIA; ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HEPATITIS C, CHRONIC; HUMANS; PRODRUGS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 59449100693     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656560802594459     Document Type: Article

References (34)

1. World Health Organization. Hepatitis C. Available from: www.who.int/mediacentre/factsheets/fs164/en/[Last accessed 24 July 2008[
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958-65
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-82
4. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140(5):346-55
5. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123(4): 1061-9
6. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38(3):645-52
7. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126(4): 1015-23
8. Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007;5(1):124-9
9. Sulkowski MS, Wasserman R, Brooks L, et al. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004; 11(3):243-50
10. Gentile I, Viola C, Reynaud L, et al. Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit. J Interferon Cytokine Res 2005;25(5):283-5
11. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002;123(1):141-51
12. Jarvis SM, Thorn JA, Glue P. Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters. Br J Pharmacol 1998;123(8):1587-92
13. Gaeta GB, Precone DF, Felaco FM, et al. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C. Aliment Pharmacol Ther 2002;16(9):1633-9
14. Bodenheimer HC Jr, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997;26(2):473-7
15. Martin LM, Younossi ZM, Price LL, et al. The impact of ribavirin-induced anemia on health-related quality of life [abstract 600a]. Presented at 56th Annual Meeting of the American Association for the Study of Liver Diseases; 11-15 November 2005; San Francisco, CA
16. Dieterich DT, Wasserman R, Bräu N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003;98(11):2491-9
17. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004;126(5):1302-11
18. Younossi ZM, Ong, JP, Collantes R, et al. Darbepoetin alfa for ribavirin-induced anemia in patients with chronic hepatitis C treated with pegylated interferon and ribavirin: a preliminary analysis [abstract]. Presented at Digestive Disease Week; 15-20 May 2004; New Orleans, LA
19. Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007;46(2):371-9
20. Wu JZ, Walker H, Lau JY, et al. Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob Agents Chemother 2003;47(1):426-31
21. Wu JZ, Larson G, Hong Z. Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin. Antimicrob Agents Chemother 2004;48(10):4006-8
22. Lin CC, Yeh LT, Vitarella D, et al. Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. Antivir Chem Chemother 2003; 14(3): 145-52
23. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999;19(Suppl 1):17-24
24. Aora S, Xu C, Teng A, et al. Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. J Clin Pharmacol 2005 ;45 (3): 275-85
25. Gish RG, Arora S, Reddy KR, et al. Virological response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol 2007;47(1):51-9
26. Benhamou Y, Pockros P, Rodriguez-Torres M, et al. The safety and efficacy of viramidine plus PegIFN alfa-2b versus ribavirin plus PegIFN alfa-2b in therapy-naïve patients infected with HCV: phase 3 results (VISER1) [abstract 751]. J Hepatol 2006;44:S273
27. Valeant Pharmaceuticals Reports VISER2 Results for Viramidine . Company Initiates Phase 2b Weight-Based Dose-Ranging Study. Available from: http://www.valeant.com/media Center/newsArticle/newsArticle.jspf?objectId =4174 [Last accessed 24 July 2008[
28. Valeant Pharmaceuticals Initiates Taribavirin Phase 2b Clinical Study. Available from: www.valeant.com/mediaCenter/newsArticle/newsArticle.jspf? objectId =4192 [Last accessed 24 July 2008[
29. Poordad F, Lawitz, E, Chun E, et al. Taribavirin comparable in efficacy to ribavirin and results in less anaemia in patients with chronic hepatitis C. Presented at EASL. Milan, Italy; 26 April 2008
30. Dadgostari S, Xu C, Yeh LT, et al. Viramidine demonstrates better safety than ribavirin in monkeys but not rats. Drug Chem Toxicol 2004;27(3):191-211
31. Lin CC, Philips L, Xu C, et al. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. J Clin Pharmacol 2004;44(3):265-75
32. Cross TJ, Antoniades CG, Harrison PM. Current and future management of chronic hepatitis C infection. Postgrad Med J 2008;84(990):172-6
33. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007;132(4):1270-8 [Epub 2007 Jan 25]
34. Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007;46(3):640-648